Utilization of angiotensin receptor blockers (ARBs) in Canada (Q20-02)

Utilization of angiotensin receptor blockers (ARBs) in Canada (Q20-02)

Q20-02_CDM

Overview

BACKGROUND
  • In 2018/19, Health Canada, the US FDA, and other regulatory agencies issued recalls of N-nitrosodimethylamine (NDMA)- and N-nitrosodiethylamine (NDEA)-contaminated angiotensin receptor blockers (ARBs).
  • Despite timely dissemination of these safety communications, little is known about how prescribers and patients responded to the notices.
AIMS OF THE STUDY

To describe and compare ARB utilization before versus after drug safety communications were issued in Canada, and to examine the characteristics of patients who completely discontinued ARBs after the communications.

Manuscripts

Presentations

Project Team

Project Lead
Robert W. Platt PhD
Project Lead
Michael Paterson MSc
Research Assistant
Carolina Moriello MSc
Site Investigator
Adrian Levy PhD
Atlantic
Site Investigator
Jacqueline Quail PhD
Saskatchewan
Site Investigator
Michael Paterson MSc
Ontario
Site Investigator
Dan Chateau PhD
Manitoba
Analyst
Shenzhen Yao MSc
Saskatchewan
Analyst
David Stock PhD
Atlantic
Analyst
Fangyun Wu MSc
Ontario
Analyst
Matthew Dahl BSc
Manitoba